{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:15:50Z","timestamp":1790720150882,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,11]]},"DOI":"10.7759\/cureus.64302","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:35:22Z","timestamp":1720686922000},"source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological Trends in the Management of Atopic Dermatitis: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Drishti M","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarshlata","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Madke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani D","family":"Jangid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talasila","family":"Sree Ramya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Atopic dermatitis","author":"Kolb L","year":"2024","unstructured":"Kolb L, Ferrer-Bruker SJ. Atopic dermatitis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/children8111057","article-title":"Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients","volume":"8","author":"Kelly KA","year":"2021","unstructured":"Kelly KA, Balogh EA, Kaplan SG, Feldman SR. Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients. Children (Basel). 2021, 8:1057. 10.3390\/children8111057","journal-title":"Children (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/DNND.S452009","article-title":"Review of pharmacotherapeutic targets in Alzheimer\u2019s disease and its management using traditional medicinal plants","volume":"14","author":"Tripathi PN","year":"2024","unstructured":"Tripathi PN, Lodhi A, Rai SN, et al.. Review of pharmacotherapeutic targets in Alzheimer\u2019s disease and its management using traditional medicinal plants. Degener Neurol Neuromuscul Dis. 2024, 14:47-74. 10.2147\/DNND.S452009","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12122975","article-title":"A review of the recent advances in Alzheimer\u2019s disease research and the utilization of network biology approaches for prioritizing diagnostics and therapeutics","volume":"12","author":"Hajjo R","year":"2022","unstructured":"Hajjo R, Sabbah DA, Abusara OH, Al Bawab AQ. A review of the recent advances in Alzheimer\u2019s disease research and the utilization of network biology approaches for prioritizing diagnostics and therapeutics. Diagnostics (Basel). 2022, 12:2975. 10.3390\/diagnostics12122975","journal-title":"Diagnostics (Basel)"},{"key":"ref5","article-title":"New and emerging trends in the treatment of atopic dermatitis","volume":"2","author":"Gelbard CM","year":"2008","unstructured":"Gelbard CM, Hebert AA. New and emerging trends in the treatment of atopic dermatitis. Patient Prefer Adherence. 2008, 2:387-92.","journal-title":"Patient Prefer Adherence"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13596-018-0300-7","article-title":"Management and treatment of atopic dermatitis with modern therapies, complementary and alternative medicines: a review","volume":"18","author":"Chew YL","year":"2018","unstructured":"Chew YL, Al-Nema M, Ong VWM. Management and treatment of atopic dermatitis with modern therapies, complementary and alternative medicines: a review. Orient Pharm Exp Med. 2018, 18:67-76. 10.1007\/s13596-018-0300-7","journal-title":"Orient Pharm Exp Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2156587215598610","article-title":"Treatment of atopic dermatitis from the perspective of traditional Persian medicine: presentation of a novel therapeutic approach","volume":"22","author":"Choopani R","year":"2017","unstructured":"Choopani R, Mehrbani M, Fekri A, Mehrabani M. Treatment of atopic dermatitis from the perspective of traditional Persian medicine: presentation of a novel therapeutic approach. J Evid Based Complementary Altern Med. 2017, 22:5-11. 10.1177\/2156587215598610","journal-title":"J Evid Based Complementary Altern Med"},{"key":"ref8","unstructured":"Holistic treatment techniques for managing atopic dermatitis. (2023). Accessed. February 3, 2024: https:\/\/www.drugtopics.com\/view\/holistic-treatment-techniques-for-managing-atopic-dermatitis."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17039.1","article-title":"Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?","volume":"8","author":"Alexander H","year":"2019","unstructured":"Alexander H, Patton T, Jabbar-Lopez ZK, Manca A, Flohr C. Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?. F1000Res. 2019, 8:1000. 10.12688\/f1000research.17039.1","journal-title":"F1000Res"},{"key":"ref10","unstructured":"Current landscape of atopic dermatitis (AD). (2023). Accessed. June 29, 2024: https:\/\/www.dermatologytimes.com\/view\/current-landscape-of-atopic-dermatitis-ad-."},{"key":"ref11","unstructured":"Treatment landscape surrounding atopic dermatitis. (2023). Accessed. June 29, 2024: https:\/\/www.ajmc.com\/view\/treatment-landscape-surrounding-atopic-dermatitis."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1898530","article-title":"The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study","volume":"33","author":"Boytsov NN","year":"2022","unstructured":"Boytsov NN, Gorritz M, Wang X, Malatestinic WN, Wade RL, Goldblum OM. The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study. J Dermatolog Treat. 2022, 33:1707-17. 10.1080\/09546634.2021.1898530","journal-title":"J Dermatolog Treat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225659","article-title":"Trends in atopic dermatitis\u2014from standard pharmacotherapy to novel drug delivery systems","volume":"20","author":"Souto EB","year":"2019","unstructured":"Souto EB, Dias-Ferreira J, Oliveira J, et al.. Trends in atopic dermatitis\u2014from standard pharmacotherapy to novel drug delivery systems. Int J Mol Sci. 2019, 20:5659. 10.3390\/ijms20225659","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/676897","article-title":"Alternative, complementary, and forgotten remedies for atopic dermatitis","volume":"2015","author":"Goddard AL","year":"2015","unstructured":"Goddard AL, Lio PA. Alternative, complementary, and forgotten remedies for atopic dermatitis. Evid Based Complement Alternat Med. 2015, 2015:676897. 10.1155\/2015\/676897","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000490","article-title":"Interleukin-4\/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma","volume":"19","author":"Wu AY","year":"2019","unstructured":"Wu AY, Sur S, Grant JA, Tripple JW. Interleukin-4\/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma. Curr Opin Allergy Clin Immunol. 2019, 19:30-7. 10.1097\/ACI.0000000000000490","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413655","article-title":"Recent advances in the inhibition of the IL-4 cytokine pathway for the treatment of allergen-induced asthma","volume":"22","author":"Massey O","year":"2021","unstructured":"Massey O, Suphioglu C. Recent advances in the inhibition of the IL-4 cytokine pathway for the treatment of allergen-induced asthma. Int J Mol Sci. 2021, 22:13655. 10.3390\/ijms222413655","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194307","article-title":"Role of Janus Kinase inhibitors in therapy of psoriasis","volume":"10","author":"S\u0142uczanowska-G\u0142\u0105bowska S","year":"2021","unstructured":"S\u0142uczanowska-G\u0142\u0105bowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A. Role of Janus Kinase inhibitors in therapy of psoriasis. J Clin Med. 2021, 10:4307. 10.3390\/jcm10194307","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030384","article-title":"A new horizon for atopic dermatitis treatments: JAK inhibitors","volume":"13","author":"Tampa M","year":"2023","unstructured":"Tampa M, Mitran CI, Mitran MI, Georgescu SR. A new horizon for atopic dermatitis treatments: JAK inhibitors. J Pers Med. 2023, 13:384. 10.3390\/jpm13030384","journal-title":"J Pers Med"},{"key":"ref19","unstructured":"Janus kinase inhibitors. (2023). Accessed. June 29, 2024: https:\/\/dermnetnz.org\/topics\/janus-kinase-inhibitors."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li H","year":"2018","unstructured":"Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018, 9:1048. 10.3389\/fphar.2018.01048","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27154964","article-title":"An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022","volume":"27","author":"Crocetti L","year":"2022","unstructured":"Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules. 2022, 27:4964. 10.3390\/molecules27154964","journal-title":"Molecules"},{"key":"ref22","unstructured":"Phosphodiesterase-4 inhibitors for psoriasis. (2023). Accessed. February 3, 2024: https:\/\/www.webmd.com\/skin-problems-and-treatments\/psoriasis\/pde-4-inhibitors-psoriasis."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010023","article-title":"Phosphodiesterase-4 inhibition in the management of psoriasis","volume":"16","author":"Crowley EL","year":"2023","unstructured":"Crowley EL, Gooderham MJ. Phosphodiesterase-4 inhibition in the management of psoriasis. Pharmaceutics. 2023, 16:23. 10.3390\/pharmaceutics16010023","journal-title":"Pharmaceutics"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55393","article-title":"Advancing treatment in atopic dermatitis: a comprehensive review of clinical efficacy, safety, and comparative insights into corticosteroids, calcineurin inhibitors, and phosphodiesterase-4 inhibitors as topical therapies","volume":"16","author":"Hernandez TD","year":"2024","unstructured":"Hernandez TD, Aleman SJ, Bao-Loc-Trung M, et al.. Advancing treatment in atopic dermatitis: a comprehensive review of clinical efficacy, safety, and comparative insights into corticosteroids, calcineurin inhibitors, and phosphodiesterase-4 inhibitors as topical therapies. Cureus. 2024, 16:e55393. 10.7759\/cureus.55393","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5528372","article-title":"New biologics for the treatment of atopic dermatitis: analysis of efficacy, safety, and paradoxical atopic dermatitis acceleration","volume":"2021","author":"Qi HJ","year":"2021","unstructured":"Qi HJ, Li LF. New biologics for the treatment of atopic dermatitis: analysis of efficacy, safety, and paradoxical atopic dermatitis acceleration. Biomed Res Int. 2021, 2021:5528372. 10.1155\/2021\/5528372","journal-title":"Biomed Res Int"},{"key":"ref26","article-title":"Topical corticosteroids and topical immunomodulators","author":"Nankervis H","year":"2016","unstructured":"Nankervis H, Thomas KS, Delamere FM, Barbarot S, Rogers NK, Williams HC. Topical corticosteroids and topical immunomodulators. Scoping Systematic Review of Treatments for Eczema. NIHR Journals Library, Southampton (UK); 2016."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani F","year":"2019","unstructured":"Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019, 10:2847. 10.3389\/fimmu.2019.02847","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00809-0","article-title":"Assessment of efficacy and safety outcomes beyond week 16 in clinical trials of systemic agents used for the treatment of moderate to severe atopic dermatitis in combination with topical corticosteroids","volume":"24","author":"Silverberg JI","year":"2023","unstructured":"Silverberg JI, Armstrong A, Blauvelt A, Reich K. Assessment of efficacy and safety outcomes beyond week 16 in clinical trials of systemic agents used for the treatment of moderate to severe atopic dermatitis in combination with topical corticosteroids. Am J Clin Dermatol. 2023, 24:913-25. 10.1007\/s40257-023-00809-0","journal-title":"Am J Clin Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105121","article-title":"Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review","volume":"103","author":"Park CO","year":"2024","unstructured":"Park CO, Kim SM, Lee KH, Bieber T. Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review. eBioMedicine. 2024, 103:105121. 10.1016\/j.ebiom.2024.105121","journal-title":"eBioMedicine"},{"key":"ref30","unstructured":"A study to look at the effects of a new medicine (astegolimab) in comparison to placebo - in patients with eczema (atopic dermatitis). (2023). Accessed. June 29, 2024: https:\/\/forpatients.roche.com\/en\/trials\/autoimmune-disorder\/a-study-to-assess-the-efficacy-and-safety-of-mstt1041a--5...."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs","volume":"79","author":"M\u00fcller S","year":"2024","unstructured":"M\u00fcller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy. 2024, 79:1501-15. 10.1111\/all.16009","journal-title":"Allergy"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker AM","year":"2022","unstructured":"Drucker AM, Morra DE, Prieto-Merino D, et al.. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022, 158:523-32. 10.1001\/jamadermatol.2022.0455","journal-title":"JAMA Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/jcia.2024.12974","article-title":"Comparative effectiveness of treatments on time to remission in atopic dermatitis: real-world insights","volume":"7","author":"Sato E","year":"2024","unstructured":"Sato E, Arima H, Ito K, Iwata M, Imafuku S. Comparative effectiveness of treatments on time to remission in atopic dermatitis: real-world insights. J Cutan Immunol Allergy. 2024, 7:12974. 10.3389\/jcia.2024.12974","journal-title":"J Cutan Immunol Allergy"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13980","article-title":"What is the most effective systemic treatment for atopic dermatitis?","volume":"51","author":"Banerjee N","year":"2021","unstructured":"Banerjee N, Grewal A. What is the most effective systemic treatment for atopic dermatitis?. Clin Exp Allergy. 2021, 51:1103-6. 10.1111\/cea.13980","journal-title":"Clin Exp Allergy"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.268","article-title":"The long-term safety of topical corticosteroids in atopic dermatitis: a systematic review","volume":"3","author":"Harvey J","year":"2023","unstructured":"Harvey J, Lax SJ, Lowe A, et al.. The long-term safety of topical corticosteroids in atopic dermatitis: a systematic review. Skin Health Dis. 2023, 3:e268. 10.1002\/ski2.268","journal-title":"Skin Health Dis"},{"key":"ref36","unstructured":"Long-term safety of dupilumab in adults with moderate to severe atopic dermatitis. (2023). Accessed. February 3, 2024: https:\/\/www.dermatologytimes.com\/view\/long-term-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic-dermatitis."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413388","article-title":"Safety and danger considerations of novel treatments for atopic dermatitis in context of primary cutaneous lymphomas","volume":"22","author":"Ko\u0142kowski K","year":"2021","unstructured":"Ko\u0142kowski K, Trzeciak M, Soko\u0142owska-Wojdy\u0142o M. Safety and danger considerations of novel treatments for atopic dermatitis in context of primary cutaneous lymphomas. Int J Mol Sci. 2021, 22:13388. 10.3390\/ijms222413388","journal-title":"Int J Mol Sci"},{"key":"ref38","unstructured":"Combining systemic therapies in psoriasis and atopic dermatitis. (2023). Accessed. June 30, 2024: https:\/\/www.dermatologytimes.com\/view\/combining-systemic-therapies-in-psoriasis-and-atopic-dermatitis."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X231180766","article-title":"Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: a case report","volume":"11","author":"Lansang RP","year":"2023","unstructured":"Lansang RP, Zhao IX, Lansang P. Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: a case report. SAGE Open Med Case Rep. 2023, 11:2050313. 10.1177\/2050313X231180766","journal-title":"SAGE Open Med Case Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1159\/000115892","article-title":"Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex","volume":"146","author":"Nahm DH","year":"2008","unstructured":"Nahm DH, Lee ES, Park HJ, Kim HA, Choi GS, Jeon SY. Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex. Int Arch Allergy Immunol. 2008, 146:235-40. 10.1159\/000115892","journal-title":"Int Arch Allergy Immunol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112927","article-title":"Atopic dermatitis: clinical aspects and unmet needs","volume":"10","author":"Lobefaro F","year":"2022","unstructured":"Lobefaro F, Gualdi G, Di Nuzzo S, Amerio P. Atopic dermatitis: clinical aspects and unmet needs. Biomedicines. 2022, 10:2927. 10.3390\/biomedicines10112927","journal-title":"Biomedicines"},{"key":"ref42","unstructured":"Unmet needs in the treatment of atopic dermatitis. (2023). Accessed. June 30, 2024: https:\/\/www.dermatologytimes.com\/view\/unmet-needs-in-the-treatment-of-atopic-dermatitis."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/273131-pharmacological-trends-in-the-management-of-atopic-dermatitis-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:35:29Z","timestamp":1720686929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/273131-pharmacological-trends-in-the-management-of-atopic-dermatitis-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.64302","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}